

### AMENDMENTS TO THE CLAIMS

1-43. (Cancelled)

~~1~~ ~~44~~. (Previously presented) An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:2; ~~or~~

(b) ~~the amino acid sequence of the extracellular domain of the polypeptide of~~  
~~SEQ ID NO:2; or~~

~~(c)~~ the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099.

~~wherein said extracellular domain is selected from the group consisting of amino acids 34-53, 114-121, and 181-266 of SEQ ID NO:2.~~

~~2~~ ~~45~~. (Previously presented) The isolated polypeptide of Claim ~~44~~<sup>1</sup> comprising the amino acid sequence of the polypeptide of SEQ ID NO:2.

46. (Cancelled)

47. (Currently amended) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO:2, wherein said extracellular domain is selected from the group consisting of amino acids 34-53, 114-121, and 181-266 of SEQ ID NO:2.

48. (Cancelled)

~~3~~ ~~49~~. (Previously presented) The isolated polypeptide of Claim ~~44~~<sup>1</sup> comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099.

~~4~~ ~~50~~. (Currently amended) A chimeric polypeptide comprising a polypeptide according to ~~Claim 42~~ Claim ~~44~~<sup>1</sup> fused to a heterologous polypeptide.

~~5~~ ~~51~~. (Previously presented) The chimeric polypeptide of Claim ~~50~~<sup>4</sup>, wherein the heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.

52. (Previously presented) An isolated polypeptide having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:2;

Appl. No. : 10/006,867  
Filed : December 6, 2001

(b) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO:2; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099,

wherein said extracellular domain is selected from the group consisting of amino acids 34-53, 114-121, and 181-266 of SEQ ID NO:2; and

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO:2 in rectal or lung tissue samples.

**53. (Previously presented)** The isolated polypeptide of Claim 52 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:2;

(b) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO:2; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099,

wherein said extracellular domain is selected from the group consisting of amino acids 34-53, 114-121, and 181-266 of SEQ ID NO:2; and

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO:2 in rectal or lung tissue samples.

**54. (Previously presented)** A chimeric polypeptide comprising a polypeptide according to Claim 52 fused to a heterologous polypeptide.

**55. (Previously presented)** The chimeric polypeptide of Claim 54, wherein said heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.